Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KIF5B | P33176 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 7/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7225093 | 1.00 | RET (0.50) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL6992109 | 0.88 | EPHA2 (0.53) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL7218888 | 0.88 | EPHA2 (0.53) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL5227290 | 0.84 | KDR (0.44) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL7225154 | 0.84 | RET (0.50) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL5230842 | 0.84 | KDR (0.43) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL7225147 | 0.84 | RET (0.50) | RETKIF5BKDREPHA2IRAK4 | |
| SCHEMBL24714036 | 0.78 | ENPP1 (0.48) | TSHRERBB2 | |
| SCHEMBL5231086 | 0.78 | EPHA2 (0.43) | KDREPHA2ERBB2EPHB4 | |
| Hydrochloric Acid SCHEMBL7219208 | 0.77 | KDR (0.69) | RETKIF5BKDREPHA2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| EP-1315705-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2002018351-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | RET 68/4885KIF5B 3266/4885KDR 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.